Epidemiology and outcome of candidaemia in patients with oncological and haematological malignancies: RESULTS from a population-based surveillance in Spain

Clinical Microbiology and Infection

Volumn 21, Issue 5, 2015, Pages 491.e1-491.e10

  Puig Asensio, M ^a,b   Ruiz Camps, I ^a,b   Fernandez Ruiz M ^c   Aguado, J M ^c   Munoz P ^d,e,f,g   Valerio, M ^d,e,f,g   Delgado Iribarren, A ^h   Merino, P ⁱ   Bereciartua, E ^j   Fortun J ^k   Cuenca Estrella, M ^l   Almirante, B ^a,b   Padilla, Belén ^d   Guinea, Jesús ^d   Paño, José Ramón ^m   García, Julio ^m   García, Carlos ^m   Fortún, Jesús ^k   Martín, Pilar ^k   Gómez, Elia ^k   Ryan, Pablo ⁿ   Campelo, Carolina ⁿ   Santos, Ignacio de los ^o   Buendía, Buenaventura ^o   Pérez, Beatriz ^p   Alonso, Mercedes ^p   Sanz, Francisca ^c   Merino, Paloma ⁱ   González, Fernando ⁱ   Gorgolas, Miguel ^q   Gadea, Ignacio ^q   Losa, Juan Emilio ^h   Delgado Iribarren, Alberto ^h   Ramos, Antonio ^r   Romero, Yolanda ^r   Sánchez, Isabel ^r   Zaragoza, Oscar ^l   Cuenca Estrella, Manuel ^l   Rodriguez Baño, Jesús ^s   Suarez, Ana Isabel ^s   Loza, Ana ^t   Aller, Ana Isabel ^t   Martín Mazuelos, Estrella ^t   Ruiz, Maite ^u   Garnacho Montero, José ^u   Ortiz, Carlos ^v   Chávez, Mónica ^w   Maroto, Fernando ^w   Salavert, Miguel ^x   Pemán, Javier ^x   Blanquer, José ^y   Navarro, David ^y   Camarena, Juan José ^z   Zaragoza, Rafael ^z   Abril, Vicente ^aa   Gimeno, Concepción ^aa   Hernáez, Silvia ^ab   Ezpeleta, Guillermo ^ab   Bereciartua, Elena ^j   Hernández, José L ^j   Montejo, Miguel ^j   Rivas, Rosa Ana ^ac   Ayarza, Rafael ^ac   Planes, Ana ^a   Almirante, Benito ^a   Mensa, José ^ad   Almela, Manel ^ad   Gurgui, Mercè ^ae   Sánchez Reus, Ferran ^ae   Martinez Montauti, Joaquin ^af   Sierra, Montserrat ^af   Horcajada, Juan Pablo ^ag   Sorli, Luisa ^ag   Gómez, Julià ^ag   Gené, Amadeu ^ah   Urrea, Mireia ^ah   more..

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^g INSTITUTO DE SALUD CARLOS III   (Spain)

^h HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

ⁱ HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^j HOSPITAL DE CRUCES   (Spain)

^k HOSPITAL RAMÓN Y CAJAL   (Spain)

^l INSTITUTO DE SALUD CARLOS III   (Spain)

^m HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

ⁿ HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^o HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^p HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^q Fundacion Jimenez Diaz   (Spain)

^r HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^s HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^t HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^u HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^v HOSPITAL UNIVERSITARI SAGRAT COR   (Spain)

^w HOSPITAL SAN JUAN DE DIOS DEL ALJARAFE   (Spain)

^x HOSPITAL UNIVERSITARIO LA FE   (Spain)

^y HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^z HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^aa HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^ab HOSPITAL DE BASURTO   (Spain)

^ac HOSPITAL DE GALDAKAO   (Spain)

^ad INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^ae HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^af Hospital de Niños de Barcelona   (Spain)

^ag HOSPITAL DEL MAR   (Spain)

^ah HOSPITAL SANT JOAN DE DÉU   (Spain)

more..

Author keywords

Antifungal agents; Cancer; Candidiasis; Drug resistance; Epidemiology; Fluconazole; Haematological malignancies

Indexed keywords

CORTICOSTEROID; ECHINOCANDIN; FLUCONAZOLE; ANTIFUNGAL AGENT;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOODSTREAM INFECTION; CANCER CHEMOTHERAPY; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CATHETER REMOVAL; CONTROLLED STUDY; DISEASE SURVEILLANCE; FEMALE; FUNGUS ISOLATION; HEMATOLOGIC MALIGNANCY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEYEROZYMA GUILLIERMONDII; MORTALITY; NEUTROPENIA; NONHUMAN; PICHIA KUDRIAVZEVII; PRIORITY JOURNAL; PROBABILITY; PROPENSITY SCORE; PROSPECTIVE STUDY; RISK FACTOR; SOLID TUMOR; SPAIN; SPECIES DISTRIBUTION; CANDIDA; CATHETER-RELATED INFECTIONS; CLASSIFICATION; COMPLICATION; EPIDEMIOLOGICAL MONITORING; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; NEOPLASM; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

CANDIDA; CANDIDA TROPICALIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA; CANDIDEMIA; CATHETER-RELATED INFECTIONS; EPIDEMIOLOGICAL MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; RISK FACTORS; SPAIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84930538787     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2014.12.027     Document Type: Article

References (34)

1. Kontoyiannis D.P., Marr K.A., Park B.J., Alexander B.D., Anaissie E.J., Walsh T.J., et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: Overview of the transplant-associated infection surveillance network (TRANSNET) database. Clin Infect Dis 2010, 50:1091-1100.
2. Gamaletsou M.N., Walsh T.J., Zaoutis T., Pagoni M., Kotsopoulou M., Voulgarelis M., et al. A prospective, cohort, multicentre study of candidaemia in hospitalized adult patients with haematological malignancies. Clin Microbiol Infect 2014, 20:O50-57.
3. Sipsas N.V., Lewis R.E., Tarrand J., Hachem R., Rolston K.V., Raad, et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): Stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 2009, 115:4745-4752.
4. Slavin M.A., Sorrell T.C., Marriott D., Thursky K.A., Nguyen Q., Ellis D.H., et al. Candidaemia in adult cancer patients: Risks for fluconazole-resistant isolates and death. J Antimicrob Chemother 2010, 65:1042-1051.
5. Tortorano A.M., Peman J., Bernhardt H., Klingspor L., Kibbler C.C., Faure O., et al. Epidemiology of candidaemia in europe: Results of 28-month european confederation of medical mycology (ecmm) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004, 23:317-322.
6. Hachem R., Hanna H., Kontoyiannis D., Jiang Y., Raad I. The changing epidemiology of invasive candidiasis: Candida glabrata and candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 2008, 112:2493-2499.
7. Viscoli C., Girmenia C., Marinus A., Collette L., Martino P., Vandercam B., et al. Candidemia in cancer patients: A prospective, multicenter surveillance study by the invasive fungal infection group (ifig) of the european organization for research and treatment of cancer (eortc). Clin Infect Dis 1999, 28:1071-1079.
8. Bergamasco M.D., Garnica M., Colombo A.L., Nucci M. Epidemiology of candidemia in patients with hematologic malignancies and solid tumours in brazil. Mycoses 2013, 56:256-263.
9. Puig-Asensio M., Padilla B., Garnacho-Montero J., Zaragoza O., Aguado J.M., Zaragoza R., et al. Epidemiology and predictive factors for early and late mortality in candida bloodstream infections: A population-based surveillance in spain. Cl Clin Microbiol Infect 2014, 20:O245-254.
10. Rodriguez-Tudela J.L., Arendrup M.C., Barchiesi F., Bille J., Chryssanthou E., Cuenca-Estrella M., et al. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 2008, 14:398-405.
11. Arendrup M.C., Cuenca-Estrella M., Lass-Florl C., Hope W. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin Microbiol Infect 2012, 18:E246-247.
12. Puig-Asensio M., Peman J., Zaragoza R., Garnacho-Montero J., Martin-Mazuelos E., Cuenca-Estrella M., et al. Impact of therapeutic strategies on the prognosis of candidemia in the ICU. Crit Care Med 2014, 42:1423-1432.
13. Mermel L.A., Allon M., Bouza E., Craven D.E., Flynn P., O'Grady N.P., et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 49:1-45.
14. Park K.H., Lee M.S., Lee S.O., Choi S.H., Sung H., Kim M.N., et al. Diagnostic usefulness of differential time to positivity for catheter-related candidemia. J Clin Microbiol 2014, 52:2566-2572.
15. Knaus W.A., Draper E.A., Wagner D.P., Zimmerman J.E., Apache I.I. A severity of disease classification system. Crit Care Med 1985, 13(10):818-829.
16. Paterson D.L., Ko W.C., Von Gottberg A., Mohapatra S., Casellas J.M., Goossens H., et al. Antibiotic therapy for klebsiella pneumoniae bacteremia: Implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004, 39:31-37.
17. McGregor J.C., Rich S.E., Harris A.D., Perencevich E.N., Osih R., Lodise T.P., et al. A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients. Clin Infect Dis 2007, 45:329-337.
18. Guinea J., Zaragoza O., Escribano P., Martin-Mazuelos E., Peman J., Sanchez-Reus F., et al. Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011. Antimicrob Agents Chemother 2014, 58:1529-1537.
19. Mann P.A., McNicholas P.M., Chau A.S., Patel R., Mendrick C., Ullmann A.J., et al. Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. Antimicrob Agents Chemother 2009, 53:5026-5034.
20. Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: A prospective multicenter study involving 2,441 patients. Antimicrob Agents Chem.
21. Kontoyiannis D.P., Vaziri I., Hanna H.A., Boktour M., Thornby J., Hachem R., et al. Risk factors for Candida tropicalis fungemia in patients with cancer. Clin Infect Dis 2001, 33:1676-1681.
22. Nucci M., Queiroz-Telles F., Alvarado-Matute T., Tiraboschi I.N., Cortes J., Zurita J., et al. Epidemiology of candidemia in Latin America: A laboratory-based survey. PloS One 2013, 8:e59373.
23. Almirante B., Rodriguez D., Cuenca-Estrella M., Almela M., Sanchez F., Ayats J., et al. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: Case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2006, 44:1681-1685.
24. Clancy C.J., Staley B., Nguyen M.H. In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole. Antimicrob Agents Chemother 2006, 50:3496-3498.
25. Ben-Ami R., Olshtain-Pops K., Krieger M., Oren I., Bishara J., Dan M., et al. Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection. Antimicrob Agents Chemother 2012, 56:2518-2523.
26. Pfaller M.A., Messer S.A., Woosley L.N., Jones R.N., Castanheira M. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: Application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol 2013, 51:2571-2581.
27. Cleveland A.A., Farley M.M., Harrison L.H., Stein B., Hollick R., Lockhart S.R., et al. Changes in incidence and antifungal drug resistance in candidemia: Results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis 2012, 55:1352-1361.
28. Beyda N.D., John J., Kilic A., Alam M.J., Lasco T.M., Garey K.W. FKS mutant Candida glabrata; risk factors and outcomes in patients with candidemia. Clin Infect Dis 2014, 59:819-825.
29. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
30. Ullmann A.J., Akova M., Herbrecht R., Viscoli C., Arendrup M.C., Arikan-Akdagli S., et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 2012, 18(Suppl 7):53-67.
31. Nucci M., Anaissie E., Betts R.F., Dupont B.F., Wu C., Buell D.N., et al. Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis 2010, 51:295-303.
32. Girmenia C., Martino P., De Bernardis F., Gentile G., Boccanera M., Monaco M., et al. Rising incidence of Candida parapsilosis fungemia in patients with hematologic malignancies: clinical aspects, predisposing factors, and differential pathogenicity of the causative strains. Clin Infect Dis 1996, 23:506-514.
33. Safdar A., Perlin D.S., Armstrong D. Hematogenous infections due to Candida parapsilosis: changing trends in fungemic patients at a comprehensive cancer center during the last four decades. Diagn Microbiol Infect Dis 2002, 44:11-16.
34. Blanchard E., Lortholary O., Boukris-Sitbon K., Desnos-Ollivier M., Dromer F., Guillemot D. Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case-control study in Paris, France. Antimicrob Agents Chemother 2011, 55:5358-5361.